Article

OBJECTIVE: To develop an automated and objective method to assess mobility in
Parkinson disease (PD) patients in daily-life settings and to investigate whether
accelerometer-derived measures discriminate between PD and healthy controls as
they walk and simulate activities of daily living (ADL). METHODS: Healthy older
adults (17) and patients with PD (22) wore a triaxial accelerometer on their
lower back during short walks (validation study) and during a walk around the
medical center to simulate daily activities (ADL simulation). The variability
(consistency and rhythmicity) of stepping was assessed. The patients completed
the walks before and after taking their anti-Parkinsonian medications.
Frequency-based acceleration measures included dominant frequency, amplitude
(strength of signal frequency), width (frequency dispersion), and slope (a
combination reflecting amplitude and width) of the main frequency of the power
spectral density in the 0.5- to 3.0-Hz band. A subset of the Unified
Parkinson-Disease Rating Scale provided a clinical measure of gait impairment
(UPDRS-Gait5). A PD patient and control wore the sensors for 3 days at home.
RESULTS: The width was larger, and the amplitude and slope were smaller in the PD
patients compared to the controls in the validation study and ADL simulation (P <
.02). The width decreased, and the amplitude and slope increased when patients
took anti-Parkinsonian medications (P < .007). Significant correlations were
observed between acceleration-derived measures and UPDRS-Gait5. The data obtained
at home was similar to the clinic data. CONCLUSIONS: Frequency-derived measures
are valid and sensitive estimates of stride-to-stride variability that can be
used to assess the quality and consistency of walking in patients with PD in
real-life settings.

Langue : ANGLAIS